LncRNA LINC01094 Promotes Cells Proliferation and Metastasis through the PTEN/AKT Pathway by Targeting AZGP1 in Gastric Cancer

Simple Summary Long noncoding RNAs (lncRNAs) were recently reported to play an essential role in multiple cancer types. We identified a lncRNA LINC01094, which was associated with the metastasis of GC through next-generation sequencing. The high expression of LINC01094 was associated with high T and N stages and a poor prognosis. We found that LINC01094 promotes the proliferation and metastasis of GC in vitro and in vivo. AZGP1 was found as the protein-binding partner of LINC01094 by using RNA pulldown and RNA-binding protein immunoprecipitation (RIP) assays. LINC01094 antagonizes the function of AZGP1, downregulates the expression of PTEN, and further upregulates the AKT pathway. Collectively, our results suggested that LINC01094 might predict the prognosis of GC patients and become the therapy target for GC. Abstract Long noncoding RNAs (lncRNAs) were recently reported to play an essential role in multiple cancer types. Herein, through next-generation sequencing, we screened metastasis-driving molecules by using tissues from early-stage gastric cancer (GC) patients with lymph node metastasis, and we identified a lncRNA LINC01094, which was associated with the metastasis of GC. According to the clinical data from the TCGA, GSE15459, and GSE62254 cohorts, the high expression of LINC01094 was associated with an unfavorable prognosis. Moreover, 106 clinical GC and paired normal samples were collected, and the qRT-PCR results showed that the high expression of LINC01094 was associated with high T and N stages and a poor prognosis. We found that LINC01094 promotes the proliferation and metastasis of GC in vitro and in vivo. AZGP1 was found as the protein-binding partner of LINC01094 by using RNA pulldown and RNA-binding protein immunoprecipitation (RIP) assays. LINC01094 antagonizes the function of AZGP1, downregulates the expression of PTEN, and further upregulates the AKT pathway. Collectively, our results suggested that LINC01094 might predict the prognosis of GC patients and become the therapy target for GC.

[1]  Dan Wang,et al.  LncRNA TNFRSF10A-AS1 promotes gastric cancer by directly binding to oncogenic MPZL1 and is associated with patient outcome , 2022, International journal of biological sciences.

[2]  Yun Liu,et al.  Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer , 2022, Cell Death & Disease.

[3]  Yi He,et al.  XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX) , 2022, Cancer communications.

[4]  Shuyi Wang,et al.  The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination , 2022, International journal of biological sciences.

[5]  K. Choy,et al.  Long Noncoding RNA UCA1 in Gastrointestinal Cancers: Molecular Regulatory Roles and Patterns, Mechanisms, and Interactions , 2021, Journal of oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  Ping Zhang,et al.  LINC01094/miR-577 axis regulates the progression of ovarian cancer , 2020, Journal of Ovarian Research.

[8]  Xin Li,et al.  Linc01094 Accelerates the Growth and Metastatic-Related Traits of Glioblastoma by Sponging miR-126-5p , 2020, OncoTargets and therapy.

[9]  Zhigang Chen,et al.  Long Non-coding RNA LINC01094 Promotes the Development of Clear Cell Renal Cell Carcinoma by Upregulating SLC2A3 via MicroRNA-184 , 2020, Frontiers in Genetics.

[10]  Zhao Li-qin,et al.  Silencing of LncRNA C1RL-AS1 Suppresses the Malignant Phenotype in Gastric Cancer Cells via the AKT/β-Catenin/c-Myc Pathway , 2020, Frontiers in Oncology.

[11]  I. Chau,et al.  Molecular target: pan-AKT in gastric cancer , 2020, ESMO Open.

[12]  R. Xu,et al.  MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer , 2020, Clinical and translational medicine.

[13]  Qiang Xu,et al.  LINC01094 Down-Regulates miR-330-3p and Enhances the Expression of MSI1 to Promote the Progression of Glioma , 2020, Cancer management and research.

[14]  Wei Li,et al.  LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via miR-577/CHEK2/FOXM1 axis , 2020, Cancer Cell International.

[15]  S. Fattahi,et al.  LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: A novel approach to personalized medicine , 2020, Journal of cellular physiology.

[16]  Wenbo Li,et al.  Overexpression of the zinc-α2-glycoprotein accelerates apoptosis and inhibits growth via the mTOR/PTEN signaling pathway in gastric carcinoma cells. , 2019, Life sciences.

[17]  Xiaoping Zhou,et al.  Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer , 2019, Cancer science.

[18]  Wei Zhao,et al.  PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling , 2019, Journal of immunology research.

[19]  Chenchen Liu,et al.  OnclncRNA-626 promotes malignancy of gastric cancer via inactivated the p53 pathway through interacting with SRSF1. , 2019, American journal of cancer research.

[20]  Maozhou Wang,et al.  miRNA-PDGFRB/HIF1A-lncRNA CTEPHA1 Network Plays Important Roles in the Mechanism of Chronic Thromboembolic Pulmonary Hypertension. , 2019, International heart journal.

[21]  S. Ju,et al.  Non-coding RNAs in regulating gastric cancer metastasis. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[22]  Jennifer Beatriz Silva Morais,et al.  Role of Zinc in Zinc-α2-Glycoprotein Metabolism in Obesity: a Review of Literature , 2019, Biological Trace Element Research.

[23]  Xi Liu,et al.  Expression and Function of Zinc-α2-Glycoprotein , 2019, Neuroscience Bulletin.

[24]  Wei-Wei Jiang,et al.  MiR-616-3p promotes angiogenesis and EMT in gastric cancer via the PTEN/AKT/mTOR pathway. , 2018, Biochemical and biophysical research communications.

[25]  Midie Xu,et al.  The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter , 2018, Journal of Hematology & Oncology.

[26]  Mathias J Friedrich,et al.  Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes , 2018, Nature.

[27]  Jun Yu,et al.  The Interplay of LncRNA-H19 and Its Binding Partners in Physiological Process and Gastric Carcinogenesis , 2017, International journal of molecular sciences.

[28]  Haiyang Xie,et al.  Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma , 2016, Carcinogenesis.

[29]  A. Morillon,et al.  History, Discovery, and Classification of lncRNAs. , 2017, Advances in experimental medicine and biology.

[30]  Fudong Yu,et al.  Zinc-α-2-Glycoprotein: A Candidate Biomarker for Colon Cancer Diagnosis in Chinese Population , 2014, International journal of molecular sciences.

[31]  G. Sauter,et al.  Abstract 572: Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG fusion positive, PTEN deleted prostate cancers , 2014 .

[32]  Chun-yu Huang,et al.  Decreased Expression of AZGP1 Is Associated with Poor Prognosis in Primary Gastric Cancer , 2013, PloS one.

[33]  Jeannie T. Lee,et al.  Long Noncoding RNAs: Past, Present, and Future , 2013, Genetics.

[34]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[35]  Massimo Libra,et al.  Akt as a therapeutic target in cancer. , 2008, Expert opinion on therapeutic targets.

[36]  J. LoPiccolo,et al.  Targeting Akt in cancer therapy. , 2007, Anti-cancer drugs.